MRNA

1. Top 5 Material Risks

• Commercialization and Market Uncertainty: Moderna’s ability to generate revenue depends on evolving regulatory requirements and public health recommendations. Changes in FDA policies or CDC/ACIP recommendations regarding target populations have impacted and may continue to impact demand for vaccines, making it difficult to forecast sales.
• Intense Competitive Pressure: Moderna competes with larger, well-established pharmaceutical companies like Pfizer, Sanofi, and GSK. Competitors exploit their greater size, supply chains, and purchasing power to bundle products and secure contracts, which has already resulted in Moderna being excluded from many European markets for COVID vaccines until at least year-end 2026.
• Pipeline Execution and Financial Sustainability: Moderna has adopted a more selective approach to R&DR&DResearch & Development — spending on creating new products or technologies investment due to post-pandemic commercial challenges. If Moderna fails to successfully implement its cost efficiency and prioritization programs, it may fail to meet its cash breakeven goal.
• Manufacturing and Supply Chain Complexity: The manufacturing processes for mRNA medicines are novel and complex. Moderna has experienced and may continue to encounter difficulties in product release, shelf life, testing, and storage. Failures in scaling batch sizes or quality control issues have previously led to product recalls and delays in clinical trials.
• Intellectual Property Litigation: Moderna is involved in significant patent litigation regarding mRNA technology. Moderna expects to expend substantial financial and managerial resources on these legal proceedings, and an unfavorable outcome could require Moderna to stop product development or commercialization efforts.

2. Company-Specific Risks

• Intismeran Autogene Manufacturing: This individualized cancer therapy requires a complex, rapid production turnaround measured in weeks. Failure to maintain the chain of identity for each patient’s tissue sample or unexpected batch failures could lead to product loss, adverse patient outcomes, or regulatory action.
• mRNA Platform Perception: Because few mRNA medicines are approved, negative perceptions or safety signals—such as reports of myocarditis and pericarditis associated with Spikevax—could damage the reputation of Moderna’s entire mRNA platform, leading to delays in other programs.
• Reliance on Single-Source Suppliers: Moderna depends on single-source suppliers for critical raw materials and excipients. If these suppliers face business interruptions or are acquired by competitors, Moderna may be unable to secure alternative sources quickly, disrupting the supply of its products.
• Government Funding and March-in Rights: Contracts with agencies like BARDA and DARPA include provisions that allow the U.S. government to exercise "march-in rights" if it determines that adequate steps have not been taken to commercialize an invention or if government action is necessary to meet public health needs, potentially forcing Moderna to grant licenses to third parties.

3. Regulatory/Legal Risks

• Most-Favored-Nation (MFN) Pricing: Executive orders and potential rulemaking regarding MFN pricing models in the U.S. could tie Moderna’s domestic pricing to international reference prices, potentially forcing Moderna to choose between reduced patient access internationally or lower U.S. revenues.
• Post-Marketing Commitments: The FDA requires Moderna to conduct post-marketing studies for mRNA-1273, including assessments of myocarditis and pericarditis risks. Failure to comply with these or other post-approval regulatory requirements can lead to warning letters, injunctions, or the revocation of regulatory authorizations.
• Foreign Corrupt Practices Act (FCPA): Because hospitals in many foreign jurisdictions are government-operated, payments to doctors or hospital employees for clinical trials can be deemed improper payments to government officials, exposing Moderna to FCPA enforcement actions and potential suspension from trading on U.S. exchanges.
• Data Privacy and Security: Moderna is subject to the EU GDPR and UK GDPR, which impose strict rules on transferring personal data to the U.S. and other countries. Violations can result in large penalties and mandatory data breach notifications, which could disrupt clinical trial operations.

4. Financial Impact Map

• Commercialization and Market Uncertainty → Product Sales → Demand for COVID and RSV vaccines may not materialize consistent with projections.
• Intense Competitive Pressure → Product Sales → Lower revenues due to discounts, rebates, and exclusion from European markets.
• Pipeline Execution and Financial Sustainability → Cash and Cash Equivalents → Failure to meet cash breakeven goal necessitates additional funding.
• Manufacturing and Supply Chain Complexity → Cost of Goods Sold → Increased costs from wasted stock, product recalls, and exit commitments with suppliers.
• Intellectual Property Litigation → Operating Expenses → Substantial financial resources diverted to legal proceedings and potential damages for infringement.